TScan Therapeutics Q1 2026 Earnings Report

TScan Therapeutics EPS Results

• Actual EPS: -$0.22
• Consensus EPS: -$0.22
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

TScan Therapeutics Revenue Results

• Actual Revenue: $0.98 million
• Expected Revenue: $2.50 million
• Beat/Miss: Missed by -$1.52 million
• YoY Revenue Growth: N/A

TScan Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/6/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, May 6, 2026
• Conference Call Time: 7:00AM ET

TScan Therapeutics (NASDAQ:TCRX) is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors. TScan has established strategic collaborations with major pharmaceutical partners to advance its lead candidates through clinical development. These partnerships enable the company to combine its TCR discovery capabilities with the resources and expertise of established drug developers, while retaining the ability to progress additional assets independently.

Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan Therapeutics went public in late 2021. Under the leadership of Chief Executive Officer Kenneth Song, the company employs a multidisciplinary team of immunologists, molecular biologists and data scientists. While its core operations are based in the United States, TScan’s research partnerships and clinical trial activities extend globally, reflecting its ambition to deliver novel T-cell therapies to patients around the world.